Aukera Therapeutics is developing a novel protein therapy, to treat ALS (also known as Lou Gehrigs disease), a rare but devastating neurodegenerative disease that is rapidly progressive and invariably fatal, usually within 3-5 years. There is only one FDA approved drug for ALS which extends life only 2-3 months and has no effect on the symptoms of the disease. Replacement therapy with Angiogenin, has shown significant effect on both survival and motor function in ALS mice studies.

2010 Boston Silver Winner